Forbion announces first close of its new BioEconomy Fund I: …

Jun 20, 2024 · Sander Slootweg, Managing Partner and co-founder of Forbion said, “The launch of BioEconomy Fund I is further evidence of Forbion’s commitment to creating positive impact. …

CouponFollow Extension

$175
OFF

Forbion Co-leads $175 Million Series B Financing Of Mariana …

2 days from now

Sep 7, 2023 · Naarden, The Netherlands and Munich, Germany – 7 September, 2023 – Forbion, a leading European life sciences venture capital firm, today announces that it has co-led, …

forbion.com

€75
OFF

Forbion Announces First Close Of Its New BioEconomy Fund I: …

2 days from now

Jun 20, 2024 · Forbion, a leading European life sciences venture capital firm, announces the first close of its new fund strategy, Forbion BioEconomy Fund I at €75 million.Forbion BioEconomy …

yahoo.com

€75
OFF

Forbion Raises New Fund To Address ‘planetary Health Challenges’

2 days from now

Jul 23, 2024 · Forbion, a life sciences venture capital firm, has held a first close on €75 million for Forbion BioEconomy Fund I, which is targeting €150 million.. Investors include KfW Capital, …

newprivatemarkets.com

€1.35
OFF

Forbion Raises €1.35B To Invest In Life Science Companies

2 days from now

Apr 19, 2023 · Sander Slootweg, managing partner and co-founder of Forbion said: “We are extremely proud of the confidence investors have placed in us as evidenced by the €1.35 …

labiotech.eu

$138
OFF

Forbion-backed Biotech Raises $138M To Develop ALS Drug

2 days from now

Nov 14, 2023 · VectorY launched in 2021 with the backing of Forbion, which founded the company the year before alongside Sander van Deventer, the company’s CEO and a Forbion …

biopharmadive.com

€129
OFF

Forbion Co-leads €129 Million Series A Financing Of VectorY, One …

2 days from now

Nov 13, 2023 · Round co-led by Forbion and EQT Life SciencesFinancing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral …

yahoo.com

€600
OFF

Forbion Announces First Close Of Forbion Growth Opportunities …

2 days from now

Jun 9, 2022 · Forbion expects to reach its €600 million hard cap, completing the raising of Forbion Growth Opportunities Fund II over the summer. Sander Slootweg, Managing Partner and co …

yahoo.com

€1.35
OFF

Forbion Raises €1.35 Billion Across Two Funds - GlobeNewswire

2 days from now

Apr 19, 2023 · Sander Slootweg, Managing Partner and co-founder of Forbion said: “We are extremely proud of the confidence investors have placed in us as evidenced by the €1.35 …

globenewswire.com

€2
OFF

Forbion's €2B Funds Are Largest Yet, With 30 Biotechs To Benefit

2 days from now

Oct 15, 2024 · Netherlands- and Germany-based Forbion exceeded its targets for its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, by bringing in 1.2 billion …

fiercebiotech.com

$505
OFF

Forbion Aims New €470M Late-stage Fund At Bets Enabled By …

2 days from now

Jun 9, 2022 · Forbion is back with another late-stage investment fund. Two years after making its first foray into the space, the VC shop has returned with a larger €470 million ($505 million) …

fiercebiotech.com

$100
OFF

Forbion Co-leads $100 Million Series A Funding In Navigator …

2 days from now

Naarden, August 27, 2024 – Forbion, a leading global life sciences venture capital firm with deep expertise in Europe , today announces its participation as lead investor in the closing of a …

forbion.com

€1.35
OFF

Forbion Raises €1.35 Billion Across Two Funds - Yahoo Finance

2 days from now

Apr 19, 2023 · Sander Slootweg, Managing Partner and co-founder of Forbion said: “We are extremely proud of the confidence investors have placed in us as evidenced by the €1.35 …

yahoo.com

$245
OFF

Forbion Co-leads $245 Million Series A Financing Of Aiolos

2 days from now

Oct 24, 2023 · SAN FRANCISCO AND LONDON – October 24, 2023 - Forbion, a leading European life sciences venture capital firm, today announces that it has co-led a $245 million …

forbion.com

FAQs about Forbion announces first close of its new BioEconomy Fund I: … Coupon?

Does forbion invest in Mariana oncology?

Naarden, The Netherlands and Munich, Germany – 7 September, 2023 – Forbion, a leading European life sciences venture capital firm, today announces that it has co-led, together with Deep Track Capital, an oversubscribed $175 million Series B financing in Mariana Oncology, the first investment by its Forbion Ventures Fund VI. ...

What is forbion bioeconomy Fund I?

Notes for Editors: Forbion BioEconomy Fund I is a newly launched investment strategy of Forbion, a leading European life sciences venture capital firm. The fund focuses on investing in innovative biotech companies that develop sustainable solutions across four sectors: Food, Agriculture, Materials and Environment Technologies. ...

What happened to the forbion Ventures Fund?

Earlier this year, Forbion announced the final close of its Forbion Ventures Fund VI, which reached the hard cap amount of €750 million and, alongside the close of the Forbion Growth Opportunities Fund II at €600 million, represented Forbion’s largest fundraising to date. ...

Who is forbion?

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Boston and Germany. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. ...

Who manages the forbion Ventures Fund VI & Growth Opportunities Fund II?

The Forbion Ventures Fund VI and the Forbion Growth Opportunities Fund II will be managed by Forbion’s highly specialized and experienced investment team and supported by a high-caliber group of Operating Partners, Venture Partners and Advisers. For more information, please contact: About Forbion ...

What is the forbion Ventures Fund?

The Forbion Ventures Fund VI is focused on building companies at an earlier stage of development and the Forbion Growth Opportunities Fund II supports the expansion of late-stage life sciences companies. ...